Molbio Diagnostics has raised ₹281.5 crore from anchor investors at the upper price band of ₹807 per share. The company’s upcoming IPO, which aims to raise up to ₹940 crore, opens for public subscription on August 10. Investors may monitor the company's reliance on its 'Truenat' platform and the competitive diagnostics market.
Molbio Diagnostics, a point-of-care diagnostics company, has completed its anchor investor book ahead of its initial public offering (IPO). The firm raised ₹281.5 crore by allocating approximately 34.88 lakh shares to institutional investors. This allotment was priced at ₹807 per share, which is the upper end of the price band set for the public offer.
Strong Institutional Participation
The anchor portion saw demand from several global and domestic institutions. Investors included names like Goldman Sachs, BlackRock Global Funds, and Mirae Asset. Domestic mutual funds were particularly active, with multiple fund houses participating across several schemes. This institutional interest often provides a signal about market sentiment toward a company’s business model before the retail portion opens.
IPO Structure and Financials
The full IPO is scheduled to open for public subscription on August 10 and will close on August 12. The issue size is expected to range between ₹904 crore and ₹940 crore. The offer is a mix of a fresh issue of shares worth up to ₹200 crore and an offer for sale (OFS) where existing stakeholders will sell their holdings. The shares are expected to list on the stock exchanges, the NSE and BSE, on August 17.
Financially, the company reported revenue of ₹1,445 crore and a profit of ₹164 crore for the financial year ending March 31, 2026. These figures offer a baseline for investors to evaluate the company's current scale of operations.
Strategic Expansion and Risks
The company is using the funds raised from the fresh issue for specific growth initiatives. Of the proceeds, ₹106 crore is designated for research and development facilities, while ₹72 crore is allocated for plant and machinery. This focus on capital spending is intended to enhance production capacity and expand its product offerings.
Investors may note that the company relies heavily on its 'Truenat' platform for a significant portion of its revenue. This platform provides molecular testing for diseases like tuberculosis, COVID-19, and HIV. Because the business is concentrated on this specific technology, any change in demand for this platform or new technological breakthroughs by competitors could impact the company’s performance. Additionally, the diagnostics sector in India is highly competitive, with many players vying for market share in both urban and resource-limited settings. Understanding how effectively the company can use the new funds to maintain its competitive edge will be a key factor for shareholders in the future.